Neovascular Glaucoma Clinical Trial
— LucNVG0108Official title:
An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma
Proliferative ischemic retinopathies lead to a formation of abnormal vessels on the iris
surface induced by an increased level of vascular endothelial growth factor (VEGF). In
progressive stages fibrovascular membranes occlude the anterior chamber angle which inhibits
aqueous outflow resulting in neovascular glaucoma. The increased intraocular pressure is
often difficult to control and frequently results in loss of vision.
The aim of this study is to analyze the short- and long-term outcome after adjuvant
intraocular Ranibizumab application in patients with neovascular glaucoma and rubeosis and
to analyze the role of ranibizumab within a holistic treatment regime.
Status | Completed |
Enrollment | 20 |
Est. completion date | July 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. neo-vascular glaucoma or rubeosis - definition of neo-vascular glaucoma: patient with iris neovascularization with intraocular pressure elevation (exceeding 21 mmHg) - definition of rubeosis: patient with iris neovascularization without intraocular pressure elevation (=21 mmHg) 2. an available follow-up of 12 months 3. written informed consent 4. visual acuity of light perception or better. Exclusion Criteria: 1. history or evidence of severe cardiac disease (e.g., NYHA functional class III or IV) 2. clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction or revascularization with 6 months 3. ventricular tachyarrhythmias requiring ongoing treatment 4. History or evidence clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation 5. Clinically significant impaired renal or hepatic function 6. Stroke within 12 month before trial entry. 7. Known serious allergies to the fluorescein dye use in angiography 8. Known contraindications to the components of Lucentis® formulation. Ocular concomitant conditions/ diseases 1. Active intraocular inflammation (grade trace or above) in either eye 2. Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye 3. History of uveitis in either eye 4. Treatment with anti-angiogenic drugs (pegaptanib sodium, anecortave acetate,bevacizumab, ranibizumab, etc.) or intravitreal corticosteroids in either eye within 4 months prior to inclusion 5. Angle block glaucoma 6. Phthisis 7. Intraocular Pressure <10mmHg Compliance/ Administrative 1. Previous participation in any clinical studies of investigational drugs (excluding vitamins and minerals) within 1 month (or a period corresponding to 5 half-lives of the investigational drug, whatever is longer) prior to inclusion 2. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent. 3. Pregnant or nursing (lactating) women 4. Inability to comply with study or follow-up procedures. 5. Any treatment with an investigational agent in the past 60 days for any condition. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | University of Lübeck - Department of Ophthalmology | Lübeck |
Lead Sponsor | Collaborator |
---|---|
University of Luebeck |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change of degree of iris rubeosis | Main outcome measure is the change of degree of iris rubeosis as documented by iris fluorescein angiography as measured 12 months after the first ranibizumab injection. | 12 Months | No |
Secondary | changes in intraocular pressure | • to document changes in intraocular pressure measurements with the Goldmann applanation tonometer | 12 Months | No |
Secondary | changes in best corrected visual acuity (BCVA) | • to document changes in best corrected visual acuity (BCVA) measured on 4 meters | 12 Months | No |
Secondary | numbers of additional interventions | • to document numbers of additional interventions or anti-glaucomatous medications 12 months after injection | 12 Months | No |
Secondary | quality of life | • to document changes of quality of life | 12 Months | No |
Secondary | Number of adverse events in all participants | • to evaluate the safety of intravitreal injections of ranibizumab (0.5 mg) as adjunctive in patients with rubeosis and neovascular glaucoma using the number of adverse events. | 12 Months | Yes |
Secondary | changes in gonioscopy | • to document changes in gonioscopy of the anterior chamber angle | 12 Months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00491712 -
Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection
|
N/A | |
Recruiting |
NCT04519619 -
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
|
||
Completed |
NCT04970251 -
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
|
N/A | |
Completed |
NCT02805257 -
Ahmed Glaucoma Valve Surgery With Mitomycin-C
|
Phase 2 | |
Recruiting |
NCT02067013 -
Analysis of Aqueous and Vitreous Humor
|
Phase 2 | |
Completed |
NCT00524758 -
Oculusgen (Ologen) Glaucoma MMC Control in Estonia
|
Phase 3 | |
Withdrawn |
NCT00727038 -
Lucentis for New Onset Neovascular Glaucoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02947867 -
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
|
Phase 2/Phase 3 | |
Completed |
NCT01711879 -
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
|
N/A | |
Terminated |
NCT02260219 -
Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma
|
N/A | |
Withdrawn |
NCT00441181 -
Effects of Travoprost on Neovascular Glaucoma
|
N/A | |
Completed |
NCT01051583 -
Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma
|
Phase 2 | |
Completed |
NCT05156021 -
A Study on the Treatment Strategy of NVG Secondary to PDR
|
N/A | |
Terminated |
NCT01301378 -
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
|
N/A | |
Not yet recruiting |
NCT05316142 -
Any Unique Identifier Assigned to the Protocol by the Sponsor
|
N/A | |
Recruiting |
NCT04844619 -
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
|
Phase 1 | |
Completed |
NCT03154892 -
The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
|
N/A |